CME / ABIM MOC

Updates From ADA 2022: Emerging Insulins and Approaches to Improve Patient Care

Authors: Juan Pablo Frias, MD; Anne L. Peters, MD; Ildiko Lingvay, MD, MPH, MSCS; Richard E. Pratley, MD; Carol Wysham, MD
CME / ABIM MOC Released: 9/22/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/22/2023, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for primary care physicians, diabetologists & endocrinologists, cardiologists, and nephrologists.

The goal of this activity is that learners will be more knowledgeable about safety and efficacy data on emerging insulins.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data presented at ADA 2022 related to once-weekly basal insulin therapy
Demonstrate greater confidence in their ability to
- Differentiate emerging once-weekly basal insulins from currently available basal insulins

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Juan Pablo Frias, MD

Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, California

Disclosures

Juan Pablo Frias, MD, has the following relevant financial relationships:
Consultant or advisor for: Akero; Altimmune; Axcella Health; Becton Dickenson; Boehringer Ingelheim; Carmot Therapeutics; Echosens; Eli Lilly; Gilead; Intercept; Metacrine; Merck; Novo Nordisk; Pfizer; Sanofi; 89bio
Speaker or member of speakers bureau for: Eli Lilly; Merck; Sanofi
Research funding from: Akero; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Intercept; IONIS; Janssen; Madrigal; Metacrine; Merck; NorthSea Therapeutics; Novartis; Novo Nordisk; Oramed; Pfizer; Poxel; Sanofi

Anne L. Peters, MD

Professor of Clinical Medicine
University of Southern California
Keck School of Medicine
Los Angeles, California

Disclosures

Anne L. Peters, MD, has the following relevant financial relationships:
Consultant or advisor for: Abbott Diabetes Care; AstraZeneca; Lilly; Novo Nordisk; ShouTi; Vertex; Zealand
Research funding from: Abbott Diabetes Care; Dexcom; Insulet
Stock options from: Omada Health
Owns stock (publicly traded) in: Teladoc

Ildiko Lingvay, MD, MPH, MSCS

Professor of Medicine
Department of Internal Medicine/ Endocrinology
Department of Population and Data Sciences
Medical Director
Office of Clinical Trials Management
University of Texas Southwestern Medical Center
Dallas, Texas

Disclosures

Ildiko Lingvay, MD, MPH, MSCS, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly; GI Dynamics; Intarcia; Intercept; Janssen; Mannkind; Merck; Mylan; Novartis; Novo Nordisk; Pfizer; Sanofi; Shionogi; Target RWE; Valeritas; Zealand Pharma
Research funding from: Boehringer Ingelheim; Novo Nordisk
Contracted researcher for: Merck; Mylan; Novo Nordisk; Pfizer; Sanofi

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida

Disclosures

Participation by Dr Pratley does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Richard E. Pratley, MD, has the following relevant financial relationships:
Consultant or advisor for: Bayer AG; Corcept Therapeutics Incorporated; Dexcom; Hanmi Pharmaceutical Co.; Merck; Novo Nordisk; Pfizer; Sanofi; Scohia Pharma Inc.; Sun Pharmaceutical Industries
Speaker or member of speakers bureau for: Novo Nordisk
Research funding from: Hanmi Pharmaceutical Co.; Metavention; Novo Nordisk; Poxel SA

Carol Wysham, MD

Clinical Professor of Medicine
University of Washington School of Medicine
Rockwood/MultiCare Center for Diabetes and Endocrinology
Spokane, Washington

Disclosures

Carol Wysham, MD, has the following relevant financial relationships:
Contracted researcher for: Abbott; Corcept; Eli Lilly; Novo Nordisk; Regeneron; Vanda

Editor

Anne G. Le, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Anne G. Le, PharmD, has no relevant financial relationships.

Compliance Reviewers

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Lisa Simani, APRN, MS, ACNP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME / ABIM MOC

Updates From ADA 2022: Emerging Insulins and Approaches to Improve Patient Care

Authors: Juan Pablo Frias, MD; Anne L. Peters, MD; Ildiko Lingvay, MD, MPH, MSCS; Richard E. Pratley, MD; Carol Wysham, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 9/22/2022

Valid for credit through: 9/22/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Basal Insulin in Diabetes

Basal insulin continues to play an important role in the treatment of patients with diabetes.
Anne L. Peters, MD

Once-Weekly Basal Insulin Icodec vs Once-Daily Insulin Glargine: Hypoglycemia

A novel once-weekly basal insulin is in development – what is its risk of hypoglycemia?
Ildiko Lingvay, MD, MPH, MSCS

Once-Weekly Basal Insulin Icodec: Different Subcutaneous Injection Regions

A novel once-weekly basal insulin is in development – does injection site matter?
Richard E. Pratley, MD

Once-Weekly Basal Insulin Fc (BIF): Safety and Efficacy

A novel once-weekly basal insulin is in development – how does it compare with degludec?
Juan Pablo Frias, MD

Summary – Putting It All Together

Why might a once-weekly basal insulin be needed in the treatment of diabetes?
Carol Wysham, MD

Page 1 of 6

Basal Insulin in Diabetes

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Juan Pablo Frias, MD

Anne L. Peters, MD

Ildiko Lingvay, MD, MPH, MSCS

Richard E. Pratley, MD

Carol Wysham, MD

Editor

Anne G. Le, PharmD

Compliance Reviewers

Susan L. Smith, MN, PhD

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

CME / ABIM MOC

Updates From ADA 2022: Emerging Insulins and Approaches to Improve Patient Care

Target Audience and Goal Statement

Disclosures

Faculty

Juan Pablo Frias, MD

Anne L. Peters, MD

Ildiko Lingvay, MD, MPH, MSCS

Richard E. Pratley, MD

Carol Wysham, MD

Editor

Anne G. Le, PharmD

Compliance Reviewers

Susan L. Smith, MN, PhD

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Updates From ADA 2022: Emerging Insulins and Approaches to Improve Patient Care

Contents of This CME Activity

Basal Insulin in Diabetes

Once-Weekly Basal Insulin Icodec vs Once-Daily Insulin Glargine: Hypoglycemia

Once-Weekly Basal Insulin Icodec: Different Subcutaneous Injection Regions

Once-Weekly Basal Insulin Fc (BIF): Safety and Efficacy

Summary – Putting It All Together